Venmax Drugs and Pharmaceuticals Merger Update

Meeting Date: October 24, 2026
Share Exchange Ratio: 1:1

Reader Takeaway: Integration with Hatri Pharma aims to boost margins via vertical synergy, but merger success depends on final NCLT approval.

What just happened

Venmax Drugs and Pharmaceuticals Limited has scheduled a court-convened meeting of its equity shareholders on October 24, 2026. The session, conducted via video conferencing, is specifically to seek approval for the merger of Hatri Pharma Private Limited into the company. The NCLT Hyderabad Bench has mandated this process, with the scheme set to take effect from an appointed date of April 1, 2025.

Why this matters

The merger is designed to transform Venmax into a vertically integrated business. By absorbing Hatri Pharma, management expects to improve operating margins through direct procurement. The deal also focuses on optimizing the transferor company’s business operations under a unified management structure, aiming for better economies of scale and cross-selling potential.

What changes now

Existing shareholders of Venmax will see no change in their current holdings, as the merger involves issuing new shares to Hatri Pharma’s shareholders at a 1:1 ratio. These new shares will rank pari passu with existing equity. The company has already secured an observation letter from BSE regarding this scheme earlier this year.

What to track next

Shareholders should participate in the remote e-voting process, which opens on October 21 and closes on October 23, 2026. Investors must ensure their demat credentials are updated with their depository participants to exercise their voting rights. The final completion of the merger remains subject to subsequent NCLT approval and other statutory clearances.